Health & Fitness
Mon, June 25, 2012Sun, June 24, 2012Sat, June 23, 2012Fri, June 22, 2012Thu, June 21, 2012Wed, June 20, 2012Tue, June 19, 2012Mon, June 18, 2012Sun, June 17, 2012Sat, June 16, 2012Fri, June 15, 2012Thu, June 14, 2012Wed, June 13, 2012Tue, June 12, 2012Mon, June 11, 2012Sat, June 9, 2012Fri, June 8, 2012Thu, June 7, 2012Wed, June 6, 2012VentriPoint to Be Featured on "The Next Biggest Winner" on iChannel
Published in Health and Fitness on Thursday, June 14th 2012 at 4:05 GMT by Market Wire
June 14, 2012 07:00 ET
VentriPoint to Be Featured on "The Next Biggest Winner" on iChannel
SEATTLE, WASHINGTON--(Marketwire - June 14, 2012) - VentriPoint Diagnostics (TSX VENTURE:VPT)(OTCQX:VPTDF) is pleased to announce the company's President & CEO, Dr. George Adams, will appear today at 7pm (ET) on "The Next Biggest Winner" on iChannel.
Tune into the iChannel through the following cable and satellite providers.
| Provider | Station | Provider | Station | ||||
| Access | 127 | Rogers | 197 | ||||
| Amtelecom | 161 | Sasktel | 105 | ||||
| Cogeco | 136 | Shaw | 95 | ||||
| Eastlink | 151 | Source Cable | 133 | ||||
| Express Vu | 514 | Starchoice | 593 | ||||
| MTS | 282 | Telus | 115 | ||||
| Mountain Cable | 177 | Videotron | 146 |
About The Next Biggest Winner
The Next Biggest Winner is a resource for ordinary Canadians trying to understand the stock market and make savvy investments and decisions. We'll hear from the top brass at emerging public companies jockeying to position themselves as the next big guy, and will put their claims to hard-headed reality check by independent experts and analysts. With host Andra Enescu.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost- effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward- looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward- looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
